Neoborocillin throat pain honey and lemon 16 past 035760103

NEOBORO GOLADO * 16PST LI&MI S / Z

Therapeutic indications

NEO BOROCILLINA THROAT PAIN mouthwash / NEO BOROCILLIN THROAT PAIN spray for oral mucosa is used in the symptomatic treatment of irritative-inflammatory states also associated with oropharyngeal pain (e.g. gingivitis, stomatitis, pharyngitis), also as a consequence of conservative dental therapy or extractive. NEO BOROCILLINA THROAT PAIN tablets is used in the symptomatic treatment of irritative-inflammatory states also associated with oropharyngeal pain (eg gingivitis, stomatitis, pharyngitis).

Dosage and method of use

Mouthwash The recommended dose is 2–3 rinses or gargles per day with 10 ml of mouthwash (using the appropriate measuring cup), diluted in half a glass of water or pure. Oral mucosal spray The recommended dose is 2 sprays 3 times a day addressed directly to the affected area; each spray delivers 0.2 ml of solution, equivalent to 0.5 mg of active principle. Pads Adults and children over 12 years: 1 tablet to be dissolved slowly in the mouth every 3–6 hours, as needed. Do not exceed the dose of 8 tablets in 24 hours. Do not administer to children under the age of 12. Dosage changes are not necessary for the elderly.

Contraindications

Flurbiprofen is contraindicated in patients with hypersensitivity (asthma, bronchospasm, urticaria or allergic type) to flurbiprofen or to any of the excipients, and to acetylsalicylic acid or other non-steroidal anti-inflammatory drugs (NSAIDs). Third trimester of pregnancy. Administration of flurbiprofen is not recommended in nursing mothers. Do not use in patients who have a peptic ulcer or have had it in the past. Do not give the tablets to children under the age of 12 years.

Side effects

The use of NEO BOROCILLINA THROAT PAIN, especially if prolonged, can give rise to sensitization or local irritation phenomena; in such cases it is necessary to interrupt the treatment and institute, if necessary, a suitable therapy. The following undesirable effects have been reported, particularly after administration of higher doses systemically: Disorders of the blood and lymphatic system Thrombocytopenia, aplastic anemia and agranulocytosis. Disorders of the immune system Anaphylaxis, angioedema, allergic reaction. Nervous system disorders Dizziness, cerebrovascular accidents, visual disturbances, optic neuritis, migraine, paraesthesia, depression, confusion, hallucination, vertigo, discomfort, fatigue and sleepiness. Ear and labyrinth disorders Tinnitus. Respiratory, thoracic and mediastinal disorders Respiratory tract reactivity (asthma, bronchospasm and dyspnoea). Gastrointestinal disorders The most commonly observed adverse events are gastrointestinal in nature. Nausea, vomiting, diarrhea, flatulence, constipation, dyspepsia, abdominal pain, melaena, haematemesis, ulcerative stomatitis, gastrointestinal haemorrhage and exacerbation of colitis and Crohn's disease have been reported following administration of flurbiprofen. Gastritis, peptic ulcer, perforation and ulcer haemorrhage were observed less frequently. Skin and subcutaneous tissue disorders Skin disorders including rash, pruritus, urticaria, purpura and very rarely bullous dermatosis (including Stevens-Johnson syndrome, toxic epidermal necrolysis and erythema multiforme). Renal and urinary disorders Nephrotoxicity in various forms, including interstitial nephritis and nephrotic syndrome. As with other NSAIDs, rare cases of renal failure have been reported. Reporting of suspected adverse reactions Reporting suspected adverse reactions that occur after authorization of the medicinal product is important, as it allows continuous monitoring of the benefit / risk ratio of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system at www.agenziafarmaco.gov.it/it/responsabili.

Special warnings

At the recommended doses, when using the medicine in its various pharmaceutical forms, any swallowing does not, in itself, cause any harm to the patient, as these doses are much lower than those commonly used in treatments with flurbiprofen by route. systemic. NEO BOROCILLIN THROAT PAIN mouthwash and NEO BOROCILLIN THROAT PAIN spray for oral mucosa (all presentations) contain methyl parahydroxybenzoate and propyl parahydroxybenzoate as preservatives: they can cause allergic reactions (even delayed). Due to the presence of sorbitol, patients with rare hereditary problems of fructose intolerance should not take NEO BOROCILLIN THROAT PAIN mouthwash and NEO BOROCILLIN THROAT PAIN spray for oral mucosa (all presentations). NEO BOROCILLIN THROAT PAIN spray (all presentations) contains a small amount of ethyl alcohol less than 100 mg per dose. NEO BOROCILLIN THROAT PAIN mouthwash contains 12.15 vol % ethanol (alcohol), e.g. up to 960 mg per serving, equivalent to approximately 24 ml of beer, 10 ml of wine per serving. It can be harmful to alcoholics. To be taken into consideration in pregnant or lactating women, children and high-risk groups such as people with liver disease or epilepsy. NEO BOROCILLIN THROAT PAIN 0.25% spray for oral mucosa taste orange and honey and NEO BOROCILLIN THROAT PAIN 0.25% Oromucosal sprays with lemon and honey flavor also contain sunset yellow dye (E110), which can cause allergic reactions. honey contain isomalt: patients with rare hereditary problems of fructose intolerance should not take this medicine. In patients with renal, cardiac or hepatic insufficiency the drug NEO BOROCILLIN THROAT PAIN should be used with caution. It is recommended not to combine the medicine with NSAIDs. The use, especially if prolonged, of the product can give rise to sensitization phenomena or local irritation; in such cases it is necessary to interrupt the treatment and consult the doctor to establish, if necessary, a suitable therapy. Do not use for prolonged treatments. After a short period of treatment without appreciable results, consult your doctor.

Pregnancy and breastfeeding

During the first and second trimester of pregnancy, flurbiprofen should not be administered except in strictly necessary cases. The drug administered during pregnancy can delay the onset of labor and increase its duration. Administration of flurbiprofen is not recommended in nursing mothers.

Expiry and retention

Mouthwash and oral mucosal spray: No special storage conditions. Tablets: Store at a temperature not exceeding 25 ° C.

Interactions with other drugs

However, inform your doctor if you are taking other medications. As demonstrated in some clinical studies, flurbiprofen may occasionally reduce the diuretic activity of furosemide. In addition, flurbiprofen may occasionally interfere with the action of anticoagulant drugs. However, no interaction of flurbiprofen with digoxin, tolbutamide and antacids has been demonstrated.

Overdose

With the use of NEO BOROCILLIN THROAT PAIN it is rare that overdose situations can occur. Symptoms Symptoms of overdose may include nausea, vomiting and gastrointestinal irritation. Treatment Treatment should include gastric lavage and, if necessary, correction of the serum electrolyte picture. There is no specific antidote for flurbiprofen.

Active principles

NEO BOROCILLIN THROAT PAIN 0.25% mouthwash and NEO BOROCILLIN THROAT PAIN 0.25% oral mucosal spray (all presentations) 100 ml of solution contain: Active principle: Flurbiprofen 0.25 g Excipients with known effects:

NEO BOROCILLIN THROAT PAIN 0.25% spray for oral mucosa taste orange and honey and NEO BOROCILLIN THROAT PAIN 0.25% sprays for the oral mucosa lemon and honey flavor also contain the excipient with a known effect sunset yellow (E110): 100 ml of solution contain:

For the full list of excipients, see section 6.1 NEO BOROCILLIN THROAT PAIN 8.75 mg lozenges (all presentations) One tablet contains: Active principle: Flurbiprofen 8.75 mg In addition, one tablet of NEO BOROCILLIN THROAT PAIN 8.75 mg orange and honey flavored tablets and NEO BOROCILLIN THROAT PAIN 8.75 mg lemon and honey flavored tablets contains 936.45 mg of isomalt. For the full list of excipients, see section 6.1

Excipients

Mint-flavored mouthwash and oral mucosal spray Glycerol, ethyl alcohol (ethanol 96%), liquid sorbitol (not crystallizable), hydrogenated castor oil 40 polyoxyethylenate, sodium hydroxide, sodium saccharin, methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, essential oil trirettified mint, patent blue V (E 131), citric acid, purified water. Lemon and honey flavored oral mucosal spray Glycerol, ethyl alcohol (ethanol 96%), liquid sorbitol (non-crystallizable), hydrogenated castor oil 40 polyoxyethylenate, sodium hydroxide, sodium saccharin, methyl -p-hydroxybenzoate, propyl-p-hydroxybenzoate, honey flavor, lemon flavor, mint flavor, sunset yellow (E110), acid citric, purified water. Orange and honey flavored oral mucosal spray Glycerol, ethyl alcohol (ethanol 96%), liquid sorbitol (non-crystallizable), hydrogenated castor oil 40 polyoxyethylenate, sodium hydroxide, sodium saccharin, methyl-p-hydroxybenzoate, propyl-p-hydroxybenzoate, honey flavor, orange flavor, mint flavor, sunset yellow (E110), acid citric, purified water. Mint-flavored sugar-free tablets Glycerol dibeenate, acesulfame potassium, balsamic mint flavor, mannitol, copovidone. Sugar-free lemon and honey tablets Glycerol dibeenate, acesulfame potassium, lemon honey flavor, isomalt, copovidone. Sugar-free tablets with orange and honey flavor Glycerol dibeenate, acesulfame potassium, honey orange flavor, isomalt, copovidone.